HLA-C and cancer: Unlike engineered (or wild-type) TCRs that require MHC intermediaries on APCs for the activation of the T-cells, MHC expressing APCs are not required for CARs and therefore bypass some of the mechanisms by which cancer cells avoid recognition [327,329].